Purpose We review recent advances in the biologic understanding and treatment of
childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), identify …

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid
leukemia (AML) have made enormous progress during the past decades. Because AML is a …

Despite major improvements in outcome over the past decades, acute myeloid leukemia
(AML) remains a life-threatening malignancy in children, with current survival rates of∼ …

Pediatric acute myeloid leukemia is a rare and heterogeneous disease in relation to
morphology, immunophenotyping, germline and somatic cytogenetic and genetic …

Purpose Karyotype is an independent indicator of prognosis in acute myeloid leukemia
(AML) that is widely applied to risk-adapted therapy. Because AML is rare in children, the …

Early response to induction chemotherapy is a predictor of outcome in acute myeloid
leukemia (AML). We determined the prevalence and significance of postinduction residual …

Background Molecular characterization has the potential to advance the management of
pediatric cancer and high-risk hematologic disease. The clinical integration of genome …

Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal
transformation of hematopoietic precursors through the acquisition of chromosomal …

Relapsed or refractory pediatric acute myeloid leukemia (AML) is associated with poor
outcomes and relapse risk prediction approaches have not changed significantly in …

Biallelic CEBPA mutations are associated with favorable outcomes in acute myeloid
leukemia (AML). We evaluated the clinical and biologic implications of CEBPA-basic leucine …